X0306 4 2022-11-01 1 0001893653 OmniAb Operations, Inc. NONE 0001237556 FOEHR MATTHEW W 5980 HORTON STREET, SUITE 600 EMERYVILLE CA 94608 1 1 0 0 CLO & Secretary Common Stock 2022-11-01 4 A 0 26193 0.00 A 212362 D Common Stock 2022-11-01 4 D 0 212362 D 0 D Stock Option 50.96 2022-11-01 4 A 0 60878 0.00 A 2032-05-05 Common Stock 60878 60878 D Stock Option 50.96 2022-11-01 4 D 0 60878 D 2032-05-05 Common Stock 60878 0 D Stock Option 41.82 2022-11-01 4 D 0 55222 D 2024-02-12 Common Stock 55222 0 D Stock Option 31.62 2022-11-01 4 D 0 35258 D 2025-02-10 Common Stock 35258 0 D Stock Option 48.21 2022-11-01 4 D 0 22660 D 2026-02-11 Common Stock 22660 0 D Stock Option 56.41 2022-11-01 4 D 0 21271 D 2027-02-24 Common Stock 21271 0 D Stock Option 89.36 2022-11-01 4 D 0 17711 D 2028-03-02 Common Stock 17711 0 D Stock Option 66.30 2022-11-01 4 D 0 29861 D 2029-02-11 Common Stock 29861 0 D Stock Option 53.77 2022-11-01 4 D 0 29012 D 2030-02-13 Common Stock 29012 0 D Stock Option 99.75 2022-11-01 4 D 0 11475 D 2031-02-03 Common Stock 11475 0 D Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. The stock option is fully vested and exercisable. The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. /s/ Charles S. Berkman, Attorney-in-Fact 2022-11-03